BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31

BillionToOne, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$101.03+2.91 (+2.97%)

Close on Oct 19, 2026

Market cap: $5.50B
P/E (TTM): 721.6
Dividend yield: –

BillionToOne, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	305	153	72
Cost of Revenue	97	72	54
Gross Profit	208	81	17
Research & Development	49	37	22
Selling, General & Admin	143	91	64
Advertising Expenses	1.20	1.30	0.40
Operating Expenses	192	128	87
Operating Income	16	-47	-69
Interest Expense	0.10	2.39	3.27
Interest & Investment Income	7.75	5.82	3.46
Other Non-Operating Income	-8.26	5.61	-13
Gain (Loss) on Sale of Assets	-0.06	-0.13	0
Pretax Income	7.76	-42	-83
Income Tax Expense	0.31	0.03	0.01
Net Income	7.45	-42	-83
Preferred Dividends	0	–	–
Net Income to Common	2.92	-42	-83
EPS (Basic)(per share)	0.18	-4.12	-8.45
EPS (Diluted)(per share)	0.14	-4.12	-8.45
Shares Outstanding (Basic, Weighted)(shares)	16	10	9.78
Shares Outstanding (Diluted, Weighted)(shares)	21	10	9.78
EBITDA	23	-40	-64

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.3%
Operating margin: 10.9%
Net margin: 9.5%
Return on equity, FY2025: 6.5%

Financial strength

Current ratio: 11.69
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 984.5%

Valuation

P/E ratio: 721.6
Price to sales: 13.84
Price to book: 10.25
Dividend yield: –